Clinical trials located in


Yvoir city is located in Belgium. Currently, 20 clinical trials are being conducted in this city.

Yvoir is a picturesque municipality in Belgium, nestled within the province of Namur. This charming locale is distinguished by its rich natural landscapes, including the scenic Meuse River that gracefully meanders through. Yvoir is not just a feast for the eyes; it’s steeped in history, with the Poilvache ruins standing as a testament to medieval times. The area is also known for its traditional stone quarries, contributing to its unique architectural heritage. Moreover, Yvoir serves as a gateway to outdoor adventures, offering numerous hiking and cycling paths that explore its verdant surroundings.

  • CT-EU-00117746

    Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    • Capivasertib
    • Docetaxel
  • Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    • Astegolimab
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    • Vibostolimab
    • Pembrolizumab
  • Study of lacutamab in T-cell lymphoma

    This trial involves a medication called lacutamab, which will be given to patients who have a type of blood cancer known as peripheral T-cell lymphoma, and their disease has either come back after previous treatment or didn’t respond at all. Some patients in the study will receive lacutamab in combination with a common chemotherapy drugs gemcitabine and oxaliplatine, while others will get only gemcitabine and oxaliplatine. A key aim of this study is to find out if lacutamab is both safe and effective. The study is designed not to compare the two treatments directly, but to check our assumptions for deciding the number of people for the trial. The number of participants getting lacutamab is bigger.

    • Lacutamab
    • Oxaliplatine
    • Gemcitabine
  • Study on the benefits of combined therapy for high-risk non-muscle invasive bladder cancer

    This research study is focused on investigating the safety and effectiveness of a medication called Pembrolizumab (MK-3475) when combined with Bacillus Calmette-Guerin (BCG) treatment in individuals with high-risk bladder cancer that has not spread to the muscle. The study involves two groups of patients: those who have not responded well to BCG alone and those who have not received BCG previously. For the first group, the primary objective is to determine if the combination of Pembrolizumab and BCG is more effective than BCG alone in eliminating their cancer. For the second group, the goal is to assess whether the combination therapy improves the likelihood of survival without any cancer-related events compared to BCG alone.

    • Bacillus Calmette-Guerin/BCG
    • Pembrolizumab
  • Comparing favezelimab/pembrolizumab combo with standard chemotherapy for Hodgkin lymphoma

    This study is investigating a treatment for PD-(L)1-refractory, relapsed, or refractory classical Hodgkin lymphoma, a type of blood cancer. Researchers are evaluating a new drug combination known as MK-4280A (favezelimab/pembrolizumab) alongside standard drugs typically used for this condition (bendamustine or gemcitabine). The aim is to determine if MK-4280A is superior to the standard drugs in extending patients’ lifespan and slowing down disease progression. Additionally, scientists will assess the safety and tolerability of MK-4280A during the study, noting any potential side effects of the drug.

    • Favezelimab
    • Pembrolizumab
    • Bendamustine
    • Gemcitabine
  • Evaluation of Namilumab in Chronic Pulmonary Sarcoidosis

    In this study, the focus is on investigating the potential benefits of the medication Namilumab for individuals with Chronic Pulmonary Sarcoidosis, a lung disease. Following the standard structure of medical studies, the new medicine is compared to a placebo. Monthly injections are administered to all participants for six months, but the allocation of the real medicine or the placebo remains undisclosed. For those who successfully complete the initial phase without significant issues, there is an option to extend their participation for an additional 28 weeks. During this extended period, the participants will continue to receive the actual medication, allowing for the monitoring of their progress and the assessment of the medicine’s impact over a more extended duration.

    • Namilumab
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    • Pomalidomide
    • Talquetamab
    • Dexamethasone
    • Daratumumab
  • Testing new treatment for coagulation disorder

    The objective of this trial is to explore different methods of halting or reversing the blood-thinning effects of specific medications before an urgent surgery. The study compares two treatments: a new medicine named TAK-330 and a commonly used one called 4F-PCC. The goal is to determine which treatment is more effective. Participants in the study will be randomly assigned to receive either TAK-330 or 4F-PCC before their surgery, requiring a hospital stay. After the surgery, the research will assess how well the participants’ blood clotting functions during and after the procedure. The study will also monitor whether additional treatments were necessary to control bleeding. Any side effects or significant health changes will be tracked, and participants will be followed up for 30 days after the surgery to assess their recovery progress.

    • four-factor prothrombin complex concentrate/4F-PCC
    • TAK-330- new potential medication for coagulation disorders
  • Testing ravulizumab for transplant-related blood complications

    The study is examining a drug called ravulizumab used in adults and teenagers with a blood vessel disease called thrombotic microangiopathy (TMA) after a bone marrow transplant. Sometimes, new cells growing after a bone marrow transplant can cause problems in the blood vessels leading to TMA. So this study will investigate whether ravulizumab can help in this situation. In the first stage, each participant will receive the drug to determine the best dose. In the second phase, some will receive ravulizumab and best supportive care, while others will receive placebo and best supportive care. After 26 weeks of treatment, doctors will continue to monitor and record the patients’ health for another 26 weeks. Special blood tests will be done to check if the medicine is working.

    • Ravulizumab
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    • Nivolumab
  • Testing new medication for advanced malignancies

    This study is about a new drug called INCA32459 in treating select advanced malignancies. The drug works by targeting two proteins, LAG-3 and PD-1, which are found in the body. The study has two parts. In the first part, different doses of the drug will be tested to see which one is most effective and safe. In the second part, the best dose identified in part 1 will be given to more patients. Researchers will continue to monitor the patients for side effects and will track how well the drug is working against the cancer.

    • INCA32459- new potential medication for advanced cancer
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Studying Ianalumab efficacy in primary immune thrombocytopenia

    This study is testing a drug called Ianalumab along with another drug called Eltrombopag to help people with a blood disease called primary immune thrombocytopenia, or ITP. ITP causes the body to destroy its platelets, which are needed to help the blood clot. Some people with ITP do not respond well to regular steroid treatment, so this study will test whether adding Ianalumab to Eltrombopag may help them more. Participants receive varying doses of Ianalumab or placebo along with Eltrombopag, with the goal of increasing the time to treatment failure. The careful design of the study ensures precise evaluation of this potential new therapy, providing hope for improved treatment of ITP.

    • Ianalumab
    • Eltrombopag
  • Comparison of new treatment and standard care for lymphoma patients

    A new approach to treating Lymphoma, a type of cancer originating in cells constituting the body’s immune system, is being tested in this trial. Comparison is being made between a new treatment, referred to as MB-CART2019.1, and the presently conventional treatment. The MB-CART2019.1 therapy is designed to target the aberrant B cells responsible for this form of cancer. In the process of creating MB-CART2019.1, cells are extracted from the patient’s own body, modified in the laboratory to combat cancer, and subsequently reintroduced into the patient. Participants in this trial will receive either MB-CART2019.1 or the standard treatment. The standard treatment involves the use of a drug combination (rituximab, gemcitabine, oxaliplatin (R-GemOx) or bendamustine, rituximab (BR) + polatuzumab vedotin). The objective is to assess whether MB-CART2019.1 demonstrates superior efficacy compared to these conventional drugs. Patient progress will be closely monitored for approximately one year to evaluate their well-being.

    • Gemcitabine
    • Polatuzumab vedotin
    • Bendamustine
    • Rituximab
    • Oxaliplatin
    • Rituximab
  • Study on pegozafermin treatment for Severe Hypertriglyceridemia

    This research study is all about testing a medicine named pegozafermin to see how safe and effective it is for people with a condition called Severe Hypertriglyceridemia (too many triglycerides in the blood). It’s a trial that compares the medicine side by side with a placebo (injection without an active substance that doesn’t have any effect). Every patient will be randomly given either the real medicine or the placebo, and neither they nor the doctors will know which one until the end. The main aim is to see how much the medicine reduces levels of triglycerides in the blood after taking it for 26 weeks.

    • Pegozafermin
  • Testing birtamimab for safety and effectiveness in patients with severe AL Amyloidosis

    This medical study aims to investigate a drug called birtamimab to understand if it effectiveness and is safe for people in the advanced stage (Mayo Stage IV) of a disease called AL Amyloidosis. In this study, scientists are comparing the outcomes of two groups of people: one group receiving birtamimab in addition to standard-of-care chemotherapy, and another group receiving a neutral drug (placebo) along with standard-of-care chemotherapy. The goal is to assess whether the group receiving birtamimab has better results or outcomes compared to the group receiving the placebo. Patients will be chosen randomly to either receive birtamimab or placebo. The study includes an Open-label Extension (OLE) Phase, which allows participants who complete the initial trial phase to continue receiving birtamimab.

    • Birtamimab

See more clinical trials in other cities in Belgium: